Müllerian inhibiting substance/anti‑Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria

  • Authors:
    • Su Mi Kim
    • Yun Oh Kim
    • Min Kyoung Lee
    • Youn Jee Chung
    • In Cheul Jeung
    • Mee Ran Kim
    • Jang Heub Kim
  • View Affiliations

  • Published online on: October 10, 2018     https://doi.org/10.3892/ol.2018.9565
  • Pages: 532-538
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Müllerian inhibiting substance/anti‑Müllerian hormone (MIS/AMH) is a regulator of the female reproductive system, an indicator of ovarian reserve and a growth inhibitor of Müllerian duct‑derived tumors in vivo and in vitro. The objective of the present study was to analyze MIS/AMH type II receptor (MIS/AMHRII) protein and mRNA expression in healthy human endometria compared with patients with endometrial hyperplasia and endometrial cancer, providing a foundation for MIS/AMH as a biological modifier for treatment of endometrial hyperplasia and endometrial cancer. The present study included healthy endometrial tissues (n=20), simple endometrial hyperplasia tissues without atypia (n=17), complex endometrial hyperplasia tissues without atypia (n=24) and endometrial cancer tissues (n=8). The location and variation of MIS/AMHRII protein expression was observed by immunohistochemistry. The expression was graded by two pathologists and was categorized as follows: Negative, weakly positive, moderately positive or strongly positive. Reverse transcription‑quantitative polymerase chain reaction was used to quantify MIS/AMHRII mRNA expression. The expression of MIS/AMHRII protein was observed in the cytoplasm of healthy human endometria, endometrial hyperplasia and endometrial cancer cells. The frequency of MIS/AMHRII protein expression was 20.22±10.35% in the proliferative phase of the healthy endometrium and 24.09±11.73% in the secretory phase of the healthy endometrium. However, no differences were observed in the menstrual cycle phases. The frequency was 54.50±16.59% in endometrial hyperplasia without atypia, 55.10±15.87% in endometrial hyperplasia with atypia and 73.88±15.70% in endometrial cancer, indicating that expression was enhanced as the disease progressed from healthy to malignant status. In endometrial hyperplasia, MIS/AMHRII protein expression was significantly associated with histological complexity compared with atypia status. The present study demonstrated that MIS/AMHRII is present in healthy endometria, endometrial hyperplasia and endometrial cancer. The low expression frequency of MIS/AMHRII was not significantly different among normal endometrial tissues, however, the protein expression was elevated in endometrial hyperplasia and endometrial cancer. These findings indicated that the study of bioactive MIS/AMH, as a possible treatment for tumors expressing the MIS/AMH receptor, is essential.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 17 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim SM, Kim YO, Lee MK, Chung YJ, Jeung IC, Kim MR and Kim JH: Müllerian inhibiting substance/anti‑Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria. Oncol Lett 17: 532-538, 2019
APA
Kim, S.M., Kim, Y.O., Lee, M.K., Chung, Y.J., Jeung, I.C., Kim, M.R., & Kim, J.H. (2019). Müllerian inhibiting substance/anti‑Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria. Oncology Letters, 17, 532-538. https://doi.org/10.3892/ol.2018.9565
MLA
Kim, S. M., Kim, Y. O., Lee, M. K., Chung, Y. J., Jeung, I. C., Kim, M. R., Kim, J. H."Müllerian inhibiting substance/anti‑Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria". Oncology Letters 17.1 (2019): 532-538.
Chicago
Kim, S. M., Kim, Y. O., Lee, M. K., Chung, Y. J., Jeung, I. C., Kim, M. R., Kim, J. H."Müllerian inhibiting substance/anti‑Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria". Oncology Letters 17, no. 1 (2019): 532-538. https://doi.org/10.3892/ol.2018.9565